Related Experiment Video
Updated: Feb 8, 2026
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with
Soujanya Sunkaraneni1, Elizabeth Ludwig2, Jill Fiedler-Kelly2
1Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA, 01752, USA. Soujanya.Sunkaraneni@sunovion.com.
Insights
Pharmacokinetic modeling supported body weight-based dosing for eslicarbazepine acetate (ESL) in pediatric epilepsy patients. This approach enabled FDA approval for pediatric use without additional clinical trials.
Area of Science:
- Pharmacokinetics
- Pediatric Pharmacology
- Computational Modeling
Background:
- Eslicarbazepine acetate (ESL) is used for partial-onset seizures.
- Pediatric dosing requires careful consideration of body weight and drug interactions.
- Population pharmacokinetic (PopPK) modeling is a valuable tool for dose selection in pediatric populations.
Purpose of the Study:
- To develop a PopPK model for eslicarbazepine in pediatric subjects (aged 4-17 years).
- To support body weight-based dose selection for ESL in pediatric patients.
- To extrapolate adult effective doses to the pediatric population using modeling and simulation.
Main Methods:
- A one-compartment PopPK model was developed using data from pediatric subjects (2-18 years).
- Allometric scaling was applied to clearance and distribution volume based on body weight.
- Covariate analysis identified effects of body weight and concomitant antiepileptic drugs (AEDs) on ESL pharmacokinetics.
- Model evaluation included visual predictive checks and bootstrap procedures.
- Simulations were performed for target exposure matching to adult effective doses.
Main Results:
- The developed PopPK model demonstrated good performance and accuracy.
- Concomitant use of carbamazepine or phenobarbital-like AEDs was predicted to decrease eslicarbazepine exposure.
- Concomitant use of levetiracetam was predicted to slightly increase eslicarbazepine exposure.
- Model-based simulations successfully matched target exposures for pediatric doses to adult effective doses.
Conclusions:
- Population pharmacokinetic modeling and simulation effectively supported body weight-based dose selection for ESL in pediatric epilepsy.
- This model-based approach facilitated extrapolation of efficacy from adults to pediatric patients (4-17 years).
- The findings supported FDA approval for ESL in pediatric subjects without necessitating further clinical studies.
Abstract:
Modeling and simulations were used to support body weight-based dose selection for eslicarbazepine acetate (ESL) in pediatric subjects aged 4-17 years with partial-onset seizures. A one-compartment pediatric population pharmacokinetic model with formulation-specific first-order absorption, first-order elimination, and weight-based allometric scaling of clearance and distribution volume was developed with PK data from subjects 2-18 years of age treated with ESL 5-30 mg/kg/day. Covariate analysis was performed to quantify the effects of key demographic and clinical covariates (including body weight and concomitant use of carbamazepine, levetiracetam, and phenobarbital-like antiepileptic drugs [AEDs]) on variability in PK parameters. Model evaluation performed using a simulation-based visual predictive check and a non-parametric bootstrap procedure indicated no substantial bias in the overall model and in the accuracy of estimates. The model estimated that concomitant use of carbamazepine or phenobarbital-like AEDs with ESL would decrease the exposure of eslicarbazepine, and that concomitant use of levetiracetam with ESL would increase the exposure of eslicarbazepine, although the small effect of levetiracetam may not represent a true difference. Model-based simulations were subsequently performed to apply target exposure matching of selected ESL doses for pediatric subjects (aged 4-17 years) to attain eslicarbazepine exposures associated with effective and well-tolerated ESL doses in adults. Overall, model-based exposure matching allowed for extrapolation of efficacy to support pediatric dose selection as part of the submission to obtain FDA approval for ESL (adjunctive therapy and monotherapy) in subjects aged 4-17 years, without requiring an additional clinical study.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:15Drug Dosing: Geriatric Patients
01:21Drug Dosing: Obese Patients
01:25Dose-Response Relationship: Selectivity and Specificity
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism